Cosmo Pharmaceuticals

Company snapshot

Cosmo Pharmaceuticals improve people's lives by developing innovative treatments that address significant unmet clinical needs and improve clinical outcomes in the field of gastroenterology and endoscopy. Our clinical development pipeline specifically addresses innovative treatments for gastro-intestinal diseases and Colon Infections. Our effort is aimed to reduce the incidence of Colorectal Cance

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Cosmo Pharmaceuticals. Not investment advice.

• What is Cosmo Pharmaceuticals?

  Cosmo Technologies is a pharma organization headquartered in GB. Primary therapeutic focus areas include Chronic Kidney Disease Stage 5 (Dialysis Dependent), bile acid diarrhoea (BAD). NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this e

• Is Cosmo Pharmaceuticals publicly traded?

  Cosmo Pharmaceuticals appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Cosmo Pharmaceuticals develop or market?

  We link 15 drug profile(s) where Cosmo Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cosmo-technologies-ltd#company-drugs.

• What are the latest developments for Cosmo Pharmaceuticals?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Cosmo Pharmaceuticals focus on?

  Cosmo Pharmaceuticals focuses on Chronic Kidney Disease Stage 5 (Dialysis Dependent), bile acid diarrhoea (BAD) based on our analysis of their pipeline programs and drug development activities.